Deschamps I, Boitard C, Hors J, Busson M, Marcelli-Barge A, Mogenet A, Robert J J
Department of Pediatric Endocrinology and Diabetes, INSERM U30, Paris, France.
Diabetologia. 1992 Oct;35(10):951-7. doi: 10.1007/BF00401424.
To determine whether genetic markers can improve the predictive value of islet cell antibodies for development of Type 1 (insulin-dependent) diabetes mellitus, 536 siblings aged 2-29 years were consecutively enrolled in a 8-year prospective survey. The risk of developing diabetes was estimated, using life-table methods, by years of follow-up and age, according to genetic factors (shared HLA-haplotypes, DR antigens, C4 allotypes) and islet cell antibody status. Fifteen siblings (2.8%) developed Type 1 diabetes during the study period (risk 4.4% after 8 years, 4% by age 22 years). DR3,4 heterozygosity identified higher risk (16% after 8 years, 12% by age 22 years, p less than 10(-5)) than HLA-identity (10% and 7%, respectively, p less than 0.01); risks for DR3 or DR4 positive and for haplo-identical siblings were low (4%, 3% and 4.4%, respectively, NS). C4BQO also conferred significant risk (11% vs 3% in non-C4BQO siblings, p less than 0.01). The predictive value of genetic markers alone was poor (12% for DR3,4, 7% for HLA-identity, 9% for C4BQO) compared with that of islet cell antibody levels greater than 4 Juvenile Diabetes Foundation units (41%, risk 56% after 8 years, p less than 10(-7)). HLA markers significantly contributed to risk prediction in combination with islet cell antibodies: islet cell antibody-positive DR3,4+ subjects had the highest risk (70% after 8 years, predictive value 58%, p less than 10(-7)) compared with islet cell antibody-positive DR3,4- (37% and 20%, respectively) and islet cell antibody-negative DR3,4+ (5% and 3.6%, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
为了确定基因标志物是否能提高胰岛细胞抗体对1型(胰岛素依赖型)糖尿病发病的预测价值,536名年龄在2至29岁的同胞连续参加了一项为期8年的前瞻性调查。根据基因因素(共享HLA单倍型、DR抗原、C4同种异型)和胰岛细胞抗体状态,采用寿命表法,按随访年限和年龄估算患糖尿病的风险。15名同胞(2.8%)在研究期间患了1型糖尿病(8年后风险为4.4%,22岁时为4%)。与HLA相同(分别为10%和7%,p<0.01)相比,DR3,4杂合性显示出更高的风险(8年后为16%,22岁时为12%,p<10(-5));DR3或DR4阳性以及单倍型相同的同胞的风险较低(分别为4%、3%和4.4%,无统计学意义)。C4BQO也带来显著风险(非C4BQO同胞中为11%,而在C4BQO同胞中为3%,p<0.01)。与胰岛细胞抗体水平大于4个青少年糖尿病基金会单位相比,单独基因标志物的预测价值较差(DR3,4为12%,HLA相同为7%,C4BQO为9%)(胰岛细胞抗体水平大于4个青少年糖尿病基金会单位时为41%,8年后风险为56%,p<10(-7))。HLA标志物与胰岛细胞抗体联合使用时对风险预测有显著贡献:胰岛细胞抗体阳性的DR3,4+受试者风险最高(8年后为70%,预测价值为58%,p<10(-7)),相比之下,胰岛细胞抗体阳性的DR3,4-受试者(分别为37%和20%)以及胰岛细胞抗体阴性的DR3,4+受试者(分别为5%和3.6%)。(摘要截短于250词)